Growth Metrics

Fennec Pharmaceuticals (FENC) Income towards Parent Company: 2011-2025

Historic Income towards Parent Company for Fennec Pharmaceuticals (FENC) over the last 15 years, with Sep 2025 value amounting to -$623,000.

  • Fennec Pharmaceuticals' Income towards Parent Company rose 89.09% to -$623,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.4 million, marking a year-over-year decrease of 588.35%. This contributed to the annual value of -$436,000 for FY2024, which is 97.28% up from last year.
  • According to the latest figures from Q3 2025, Fennec Pharmaceuticals' Income towards Parent Company is -$623,000, which was up 80.25% from -$3.2 million recorded in Q2 2025.
  • In the past 5 years, Fennec Pharmaceuticals' Income towards Parent Company registered a high of $12.9 million during Q1 2024, and its lowest value of -$10.3 million during Q4 2022.
  • In the last 3 years, Fennec Pharmaceuticals' Income towards Parent Company had a median value of -$2.6 million in 2023 and averaged -$1.9 million.
  • Examining YoY changes over the last 5 years, Fennec Pharmaceuticals' Income towards Parent Company showed a top increase of 316.58% in 2024 and a maximum decrease of 222.47% in 2024.
  • Fennec Pharmaceuticals' Income towards Parent Company (Quarterly) stood at -$4.2 million in 2021, then slumped by 89.66% to -$10.3 million in 2022, then skyrocketed by 74.66% to -$2.6 million in 2023, then spiked by 42.67% to -$1.5 million in 2024, then spiked by 89.09% to -$623,000 in 2025.
  • Its Income towards Parent Company stands at -$623,000 for Q3 2025, versus -$3.2 million for Q2 2025 and -$1.2 million for Q1 2025.